TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28566632

Group type: EXPERIMENTAL
Intervention: Low-caffeine green tea (≥500 mL/d, with theanine ca. 15 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-caffeine green tea
Number of subjects: 20
Study: 25783756

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 30 sessions
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy comparison subjects
Number of subjects: 45
Study: 23065509

Group type: EXPERIMENTAL
Intervention: Chromosomal aberrations (specifically 6q deletions, trisomy 18, 13q deletions, 17p deletions, trisomy 4, 11q deletions)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: TP53 deletion
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Trisomy 12
Number of subjects: 174
Study: 20505665

Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension (POS) 200 mg three times daily (t.i.d.)
Number of subjects: 0
Study: 18378519

Group type: EXPERIMENTAL
Intervention: Active treatment (indapamide 1.5 mg sustained release)
Number of subjects: 3845
Study: 16360877

Group type: EXPERIMENTAL
Intervention: High self‐efficacy and high negative incentive value
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low self‐efficacy and high negative incentive value
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cognitive regulation of systolic and diastolic blood pressure and pulse pressure
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Perceived competence
Number of subjects: 80
Study: 12745193

Group type: EXPERIMENTAL
Intervention: DASH diet with losartan 50 mg daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control diet with losartan 50 mg daily
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: DASH diet with placebo
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control diet with placebo
Number of subjects: 55
Study: 11310907

Group type: EXPERIMENTAL
Intervention: Propofol with EDTA
Number of subjects: 102

Group type: COMPARATOR
Intervention: Propofol without EDTA
Number of subjects: 102
Study: 8793606

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg tablet for 7 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 23
Study: 1627417

Group type: EXPERIMENTAL
Intervention: Sequential methotrexate and fluorouracil (MTX-5-FU) followed by leucovorin
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TMX)
Number of subjects: 737

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 737
Study: 6744774

Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 360 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Methyldopa (500 to 2500 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Propranolol and Methyldopa
Number of subjects: 17
Study: 31487806

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) with Low-Fiber (LoFi) products
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: High-Fiber (HiFi) intake
Number of subjects: 73

Group type: COMPARATOR
Intervention: Maltodextrin (MD) with Low-Fiber (LoFi)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) with High-Fiber (HiFi) products
Number of subjects: 73
Study: 29069908

Group type: EXPERIMENTAL
Intervention: Initial nine-species-based selection of optical filters
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bootstrap analysis based on the larger data set
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Filter selection using all 31 species
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low-rank hypothesis
Number of subjects: 31
Study: 26440129

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound
Number of subjects: 84

Group type: COMPARATOR
Intervention: Consultative ultrasound
Number of subjects: 84
Study: 24379136

Group type: EXPERIMENTAL
Intervention: Flu-Like Symptom Index (FLSI)
Number of subjects: 0
Study: 22748820

Group type: EXPERIMENTAL
Intervention: Intravenous aspirin (300 mg) within 90 min after alteplase treatment
Number of subjects: 642

Group type: COMPARATOR
Intervention: Standard treatment (alteplase without aspirin)
Number of subjects: 642
Study: 19906503

Group type: EXPERIMENTAL
Intervention: Self-care management intervention
Number of subjects: 7677
Study: 17609331

Group type: EXPERIMENTAL
Intervention: Home-based physical therapy intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Clinic-based management
Number of subjects: 47
Study: 16059679

Group type: EXPERIMENTAL
Intervention: Dense artery sign identified via maximum intensity projections
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Increased density of the whole M1 segment with extension to M2
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Dense sylvian branch of the middle cerebral artery pattern
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Patients without a demonstrable dense artery
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Patients with 7-10 points on the Alberta Stroke Early Programme Computed Tomography Score and a dense proximal MCA
Number of subjects: 49
Study: 12244740

Group type: EXPERIMENTAL
Intervention: Product 1 (0.243% sodium fluoride with copolymer, tetrasodium pyrophosphate, and sodium tripolyphosphate in a silica base)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Product 2 (0.243% sodium fluoride, baking soda and peroxide, tetrasodium pyrophosphate, and sodium tripolyphosphate in a silica base)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Product 3 (0.243% sodium fluoride in a silica base)
Number of subjects: 126
Study: 11860782

Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 1831
Study: 8861829

Group type: EXPERIMENTAL
Intervention: PMEA (9-(2-phosphonylmethoxyethyl)adenine) administered intravenously at a dose of 1000 mg weekly for 11 weeks
Number of subjects: 10
Study: 1731046

Group type: EXPERIMENTAL
Intervention: Naloxone (0.05, 0.10, 0.15 and 0.20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 20
Study: 3937219

Group type: EXPERIMENTAL
Intervention: Cryoprecipitate from 30 donors (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Stored plasma (n = 14)
Number of subjects: 28
Study: 30586209

Group type: EXPERIMENTAL
Intervention: BRJ nitrate (8.1 mmol BRJ nitrate)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: BRJ nitrate
Number of subjects: 18

Group type: COMPARATOR
Intervention: BRJ placebo
Number of subjects: 18
Study: 29897851

Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride content, rapid rate of administration
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride content, slow rate of administration
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: 0.45% sodium chloride content, rapid rate of administration
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: 0.45% sodium chloride content, slow rate of administration
Number of subjects: 1255

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 1255
Study: 27132415

Group type: EXPERIMENTAL
Intervention: Piroxicam 10 mg/day on days 4-6 after IUI
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 260
Study: 23813113

Group type: EXPERIMENTAL
Intervention: Multifocal intraocular lenses (ReSTOR SN6AD1, ReSTOR SN60D3, ReZoom NXG, Tecnis ZMA00)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Monofocal intraocular lens (Tecnis ZA9003)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Multifocal intraocular lenses with diffractive optics and aspheric profiles
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Refractive, distance dominant lens designs
Number of subjects: 180
Study: 23377515

Group type: EXPERIMENTAL
Intervention: High-potency, multimechanism skin care regimen (NeoStrata® Skin Active)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 20712131

Group type: EXPERIMENTAL
Intervention: Single dose of oral activated charcoal (50 g) given 30 min after drugs
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Repeated doses of oral activated charcoal (20 g) given 6-72 h after LTG
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Repeated doses of oral activated charcoal (20 g) given 12-48 h after OXC
Number of subjects: 6
Study: 18466657

Group type: EXPERIMENTAL
Intervention: Low-sodium, high-potassium diet (LNAHK)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: High-calcium diet (HC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Moderate-sodium, high-potassium, high-calcium Dietary Approaches to Stop Hypertension (DASH) diet (OD)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 94
Study: 15888425

Group type: EXPERIMENTAL
Intervention: CAST plus vocational rehabilitation
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: TSSN plus vocational rehabilitation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Vocational rehabilitation alone
Number of subjects: 138
Study: 14519564

Group type: EXPERIMENTAL
Intervention: Gatehouse Project intervention
Number of subjects: 26
Study: 10085281

Group type: EXPERIMENTAL
Intervention: Topical crude honey (12 hourly application)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Local antiseptics (70% Ethanol and povidone-iodine)
Number of subjects: 50
Study: 7751892

Group type: EXPERIMENTAL
Intervention: Oophorectomy plus CAF (O+CAF)
Number of subjects: 147

Group type: COMPARATOR
Intervention: CAF (Cyclophosphamide, Doxorubicin, and Fluorouracil)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Age > or = 45 years
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Last menstruation within 1 month
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: O+CAF in patients < 45 years
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: CAF in patients > 45 years
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: O+CAF in PS O patients
Number of subjects: 147
Study: 2264899

Group type: EXPERIMENTAL
Intervention: Local anesthesia with intravenous sedation (fentanyl, midazolam, or combinations thereof)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Fentanyl, midazolam, and fentanyl/midazolam combinations as intravenous supplements
Number of subjects: 500
Study: 6449360

Group type: EXPERIMENTAL
Intervention: Carbenicillin (6 g/m(2) . 6 h) plus sisomicin (45 g/m2 . 6 h)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mezlocillin (3 g/m2 . 6 h) plus sisomicin (45 g/m2 . 6 h)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both combinations
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 22
Study: 30447958

Group type: EXPERIMENTAL
Intervention: 40-ppm nitric oxide (NO) added to the CPB circuit during cardiac surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard CPB protocol without NO)
Number of subjects: 60
Study: 26538521

Group type: EXPERIMENTAL
Intervention: SRP + moxifloxacin (MOX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SRP + placebo
Number of subjects: 40
Study: 25615542

Group type: EXPERIMENTAL
Intervention: Dynamic assessment of morphological awareness
Number of subjects: 54
Study: 23751300

Group type: EXPERIMENTAL
Intervention: Neuroplasticity-based computerized cognitive remediation program for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (age- and gender-matched children with 22q11DS)
Number of subjects: 23
Study: 21053091

Group type: EXPERIMENTAL
Intervention: Scenario of a highly accurate screening test (sensitivity 99% and specificity 99%) with manipulated prevalence (1%, 2%, 10%, 25%, 95%, or no information)
Number of subjects: 1361

Group type: COMPARATOR
Intervention: No information on prevalence
Number of subjects: 1361
Study: 19250791

Group type: EXPERIMENTAL
Intervention: Multimedia patient education program
Number of subjects: 270
Study: 16459230

Group type: EXPERIMENTAL
Intervention: 0.4 g/d of PSE in DAG-containing mayonnaise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.3 g/d of PSE in DAG-containing mayonnaise
Number of subjects: 0
Study: 15383884

Group type: EXPERIMENTAL
Intervention: No-touch technique for autologous fat harvesting
Number of subjects: 30
Study: 11298175

Group type: EXPERIMENTAL
Intervention: Midazolam 0.04 mg kg(‐1) (group 2)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Midazolam 0.04 mg kg(‐1) and lidocaine 1.5 mg kg(‐1) (group 3)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Fentanyl 1 microg kg(‐1) and lidocaine 1.5 mg kg(‐1) (group 1)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Fentanyl 1 microg kg(‐1) (group 4)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Midazolam 0.04 mg kg(‐1) (groups 2 and 3)
Number of subjects: 142
Study: 9392406

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (200 microg thrice daily for 14 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (600 microg single inhalation after 14 days treatment)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (thrice daily for 14 days)
Number of subjects: 8
Study: 8017589

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg.kg‐1 b.w.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopentone (5 mg.kg‐1 b.w.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etomidate (0.2 mg.kg‐1 b.w.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flunitrazepam and fentanyl (0.005 mg.kg‐1 b.w.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoflurane (0.4‐0.8 Vol%)
Number of subjects: 30
Study: 2465099

Group type: EXPERIMENTAL
Intervention: Active antiarrhythmic therapy (various drugs including encainide and flecainide)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Encainide and flecainide treatments
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Active therapies (general)
Number of subjects: 502
Study: 62111

Group type: EXPERIMENTAL
Intervention: Warfarin sodium (doses aimed at maintaining a 'Thrombotest' value of 10%, given from the day of admission until independent mobility or for 3 months)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Number of subjects: 160
Study: 31444192

Group type: EXPERIMENTAL
Intervention: Habit-B programme (high-intensity interval training, exercise counselling + guidance, home-based exercise support using information and communication technology, and a wearable device)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual with a wearable device
Number of subjects: 0
Study: 27155315

Group type: EXPERIMENTAL
Intervention: WHO-MetS
Number of subjects: 7932

Group type: EXPERIMENTAL
Intervention: IDF-MetS
Number of subjects: 7932

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7932

Group type: COMPARATOR
Intervention: IDF
Number of subjects: 7932

Group type: COMPARATOR
Intervention: JIS
Number of subjects: 7932

Group type: COMPARATOR
Intervention: WHO
Number of subjects: 7932
Study: 26279111

Group type: EXPERIMENTAL
Intervention: L-T4 treatment (1.6 µg/kg daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: L-T4 treatment
Number of subjects: 59
Study: 23430723

Group type: EXPERIMENTAL
Intervention: Specific antibiotics (Group A)
Number of subjects: 471

Group type: COMPARATOR
Intervention: No specific antibiotics (Group B)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 471
Study: 21208086

Group type: EXPERIMENTAL
Intervention: Chitosan-containing dentifrice (AloeDent)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nonfluoridated dentifrice (Sensodyne Mint)
Number of subjects: 16
Study: 20035686

Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment
Number of subjects: 0
Study: 18257346

Group type: EXPERIMENTAL
Intervention: Pricking blood therapy combined with acupuncture
Number of subjects: 240

Group type: COMPARATOR
Intervention: Routine western medicine (Aciclovir plaster and Aciclovir tablets)
Number of subjects: 240
Study: 15096431

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine hydrochloride with epinephrine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (placebo)
Number of subjects: 130
Study: 11495138

Group type: EXPERIMENTAL
Intervention: Active dental gel (lidocaine 25 mg/g plus prilocaine 25 mg/g)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 122
Study: 9728853

Group type: EXPERIMENTAL
Intervention: Oral antihistamines (diphenhydramine ≤ 1 mg/kg and cimetidine ≤ 4 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7802180

Group type: EXPERIMENTAL
Intervention: Oesophageal detector device
Number of subjects: 29
Study: 3281703

Group type: EXPERIMENTAL
Intervention: Coal tar bath
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oil emulsion bath
Number of subjects: 11
Study: 29663959

Group type: EXPERIMENTAL
Intervention: 4-drug fixed-dose combination (4FDC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2-drug fixed-dose combination (2FDC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single-drug reference
Number of subjects: 20
Study: 28685558

Group type: EXPERIMENTAL
Intervention: Berberine + Silymarin (BBR)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 25772742

Group type: COMPARATOR
Intervention: Everolimus-eluting stent implantation in group A (BMS restenosis)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent implantation in group B (de novo atherosclerotic lesions)
Number of subjects: 32

Group type: COMPARATOR
Intervention: DES struts protruding out of BMS in group A
Number of subjects: 32
Study: 23890459

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study: 21060780

Group type: EXPERIMENTAL
Intervention: H1N1 LAIV (live attenuated influenza vaccine)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 626
Study: 18663427

Group type: EXPERIMENTAL
Intervention: Exercise intervention (7 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 70
Study: 16801670

Group type: EXPERIMENTAL
Intervention: Family history of dementia in patients with Lewy body dementia (LBD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family history of dementia in patients with Alzheimer's disease (AD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 14499320

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) as monotherapy (n=7) or adjunctive therapy to carbamazepine (CBZ) (n=2) at dosages ranging from 25 mg to 100 mg twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 9
Study: 10707873

Group type: EXPERIMENTAL
Intervention: 0.03 microg/kg b.w. rHuIL-12
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 0.25 microg/kg b.w. rHuIL-12
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 0.50 microg/kg b.w. rHuIL-12
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: rHuIL-12 (all doses)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: rHuIL-12 (higher doses)
Number of subjects: 46
Study: 9236473

Group type: EXPERIMENTAL
Intervention: Questionnaires with positive rating on the left side
Number of subjects: 140

Group type: COMPARATOR
Intervention: Questionnaires with positive rating on the right side
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Forms with five, six, or seven response options
Number of subjects: 140
Study: 7934094

Group type: EXPERIMENTAL
Intervention: Pulsatile cardiopulmonary bypass (group I)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonpulsatile cardiopulmonary bypass (group II)
Number of subjects: 15
Study: 3259084

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 40
Study: 29532591

Group type: EXPERIMENTAL
Intervention: Satavaptan
Number of subjects: 1115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1115
Study: 28459732

Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (fluid therapy based on traditional principles)
Number of subjects: 128
Study: 26242578

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice daily, increased to 1000 mg twice daily over 6 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 100
Study: 24045239

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC)
Number of subjects: 54
Study: 21690510

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray, 55 μg/nostril daily for 2 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study: 18581467

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study: 17205943

Group type: EXPERIMENTAL
Intervention: Standard therapy plus epidural injection of 80 mg methylprednisolone and 10 mg bupivacaine
Number of subjects: 598

Group type: COMPARATOR
Intervention: Standard therapy (oral antiviral agents and analgesics) alone
Number of subjects: 598
Study: 14610642

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: HRT (Premarin 0.625 mg/day, and Provera 2.5 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 10734271

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 152

Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 152
Study: 9366539

Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Histological evaluation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lung function tests
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chest radiographs
Number of subjects: 10
Study: 1550312

Group type: EXPERIMENTAL
Intervention: Fluosol DA‐20 per cent (blood substitute)
Number of subjects: 47